Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
FLGT 
Fulgent Genetics Inc (FLGT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/14/2025: FLGT (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $30
1 Year Target Price $30
| 0 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.74% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 914.70M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 3 | Beta 0.68 | 52 Weeks Range 14.57 - 30.59 | Updated Date 11/15/2025 |
52 Weeks Range 14.57 - 30.59 | Updated Date 11/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-07 | When - | Estimate -0.2242 | Actual 0.14 |
Profitability
Profit Margin -13.62% | Operating Margin (TTM) -18.26% |
Management Effectiveness
Return on Assets (TTM) -3.63% | Return on Equity (TTM) -3.92% |
Valuation
Trailing PE - | Forward PE 7.94 | Enterprise Value 531290607 | Price to Sales(TTM) 2.9 |
Enterprise Value 531290607 | Price to Sales(TTM) 2.9 | ||
Enterprise Value to Revenue 1.68 | Enterprise Value to EBITDA -4.34 | Shares Outstanding 30912392 | Shares Floating 18939713 |
Shares Outstanding 30912392 | Shares Floating 18939713 | ||
Percent Insiders 32.81 | Percent Institutions 58.19 |
Upturn AI SWOT
Fulgent Genetics Inc
Company Overview
History and Background
Fulgent Genetics was founded in 2011. Initially focused on comprehensive genetic testing, it gained prominence during the COVID-19 pandemic with its PCR testing services. It has since expanded its offerings to include various genetic testing panels and telehealth services.
Core Business Areas
- Genetic Testing: Offers comprehensive genetic testing panels for various inherited diseases, cancers, and other conditions. Uses next-generation sequencing (NGS) technology.
- COVID-19 Testing: Provided PCR-based COVID-19 testing services, which significantly contributed to revenue growth during the pandemic. This has since drastically decreased with the end of the COVID-19 emergency declaration in the US.
- Telehealth Services: Fulgent Health offers telemedicine services.
Leadership and Structure
Ming Hsieh is the Chairman of the Board and CEO. The company has a typical corporate structure with departments focusing on R&D, sales, marketing, and operations. Brandon Perthuis is the Chief Commercial Officer.
Top Products and Market Share
Key Offerings
- Genetic Testing Panels (Inherited Diseases): Offers a wide range of genetic tests for inherited conditions. Competitors: Invitae (NVTA), Myriad Genetics (MYGN). Market share data varies; precise figures are difficult to obtain as it is a fragmented market with niche players, estimated to be around 5-10% of the market in 2023.
- Genetic Testing Panels (Oncology): Provides genetic tests for cancer risk assessment and personalized treatment decisions. Competitors: Exact Sciences (EXAS), Guardant Health (GH). Market share data varies; precise figures are difficult to obtain as it is a fragmented market with niche players, estimated to be around 5-10% of the market in 2023.
- COVID-19 Testing: Prior to 2023, COVID-19 testing made up a large part of revenue, since then has been reduced to negligible revenue.
Market Dynamics
Industry Overview
The genetic testing market is growing rapidly, driven by advancements in technology, increasing awareness of personalized medicine, and decreasing costs of sequencing. Telehealth has also seen growth and is likely to continue due to improved ease for patients. Competition is high.
Positioning
Fulgent Genetics is positioned as a provider of comprehensive and affordable genetic testing services. Its competitive advantage lies in its technological platform and efficient operations.
Total Addressable Market (TAM)
The total addressable market for genetic testing is estimated to reach hundreds of billions of dollars by 2030. Fulgent Genetics is positioned to capture a portion of this growth through its expanding product offerings and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Comprehensive Genetic Testing Platform
- Efficient Operations and Scalability
- Strong Technology Infrastructure
- Expanding Product Portfolio
- Telemedicine presence
Weaknesses
- Reliance on COVID-19 testing revenue (decreasing)
- High competition in the genetic testing market
- Need for increased brand recognition
- Vulnerable to price compression
- Significant changes in market share between quarters and years
Opportunities
- Expanding into new geographic markets
- Developing new genetic testing panels
- Forming strategic partnerships with healthcare providers
- Increasing focus on personalized medicine
- Growing telehealth capabilities
Threats
- Increased competition from established players
- Changes in reimbursement policies
- Technological advancements by competitors
- Data privacy and security concerns
- Fluctuations in demand for COVID-19 testing
Competitors and Market Share
Key Competitors
- NVTA
- EXAS
- LH
- DGX
- ILMN
Competitive Landscape
Fulgent Genetics faces strong competition from established players with larger market shares. However, Fulgent Genetics' competitive advantages include its comprehensive testing platform, efficient operations, and affordable pricing.
Major Acquisitions
Inform Diagnostics
- Year: 2022
- Acquisition Price (USD millions): 170
- Strategic Rationale: Expand cancer diagnostic capabilities and market reach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was heavily influenced by COVID-19 testing. The company's long term growth will depend on its core genetic testing offerings.
Future Projections: Analysts project continued revenue decline as COVID-19 testing revenue subsides. Future growth depends on the expansion of its core genetic testing business and its Telehealth options.
Recent Initiatives: Recent strategic initiatives include expanding its genetic testing panels, focusing on personalized medicine, and growing its telehealth platform.
Summary
Fulgent Genetics experienced rapid growth due to COVID-19 testing, but now faces the challenge of diversifying its revenue streams as testing demand declines. The company's core genetic testing business and strategic acquisitions offer potential growth opportunities. However, it faces stiff competition and needs to increase brand recognition. The company must focus on expanding product portfolio and partnerships to ensure long-term sustainability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q)
- Analyst reports
- Press releases
- Yahoo Finance
- Company Investor Relations
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is approximate and based on available information. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fulgent Genetics Inc
Exchange NASDAQ | Headquaters El Monte, CA, United States | ||
IPO Launch date 2016-09-29 | Chairman & CEO Mr. Ming Hsieh | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1313 | Website https://www.fulgentgenetics.com |
Full time employees 1313 | Website https://www.fulgentgenetics.com | ||
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.